Everyone deserves the right to breathe freely and live fully, no matter where they live. That’s why we are aiming to transform the landscape of asthma care – today and for years to come – by forging powerful partnerships with those who understand the needs of people living with asthma and advancing cutting-edge technologies to push the boundaries of scientific innovation.
Asthma remains an urgent global challenge, and solutions that rethink access to anti-inflammatory care must take a local approach. In collaboration with our partners worldwide, AstraZeneca is working to ensure earlier diagnoses, advance innovation in inhaled and targeted treatments and eliminate exacerbations for better long-term outcomes for every patient, everywhere.
Here are five ways we’re transforming access to asthma care:
1. Addressing Unmet Asthma Needs at the Point-of-Care: Improving Lung Health in Germany
AstraZeneca is changing the treatment landscape in Germany — from educating healthcare professionals about the latest scientific innovations and treatments, to improving the point-of-care experience for asthma patients.
- Through our initiative, “Time to polish your asthma therapy,” we’re educating general practitioners, pulmonologists, pharmacists and patients on the latest interventions, helping them move away from outdated emergency inhaler and steroid overuse. Our ultimate goal is to help patients take control of their asthma with the use of guideline-directed therapies.
- As a founding member of “Decade of the Lung” – an expert-led organisation dedicated to promoting lung health – AstraZeneca is calling on policymakers to incorporate asthma screenings into routine health check-ups. By meeting patients where they are at the point of care, we’re driving earlier diagnoses and supporting healthy lungs for years to come.
2. Prompting Early Asthma Intervention: Applying the Latest Diagnostic Innovations in China
While asthma is prevalent in China, it is largely undiagnosed and undertreated.1 Our aim is to introduce alternative diagnostic solutions, allowing more patients to be diagnosed and treated. We are currently evaluating a portable diagnostic technology with the aim of diagnosing 14 million more asthma and COPD patients by 2030. Earlier diagnosis and treatment have the potential to improve outcomes, including a potential reduction in mortality.
3. Promoting Asthma Care for All: Overcoming Barriers to Access in the UK
Access to asthma care doesn’t solely depend on someone’s ability to see a healthcare professional – it’s also about ensuring that these healthcare professionals are empowered to prescribe the right treatment for the right patient.
In the UK, AstraZeneca is working closely with the severe asthma expert community to improve patient outcomes while reducing inequities and barriers to care. Through supporting healthcare professionals with identification tools that proactively find uncontrolled asthma patients, homecare options and supporting optimisation of pathways that streamline patient care and resource management across a large network, we’re making treatment options more accessible to patients across England.
4. Advancing Treatment Guidelines: Improving Asthma Management Across Europe and Asia
Our work across Europe and Asia aims to close the gap between international evidence-based treatment guidelines and current clinical practices to improve patient outcomes.
- In Germany, AstraZeneca is raising awareness about guideline-directed medical treatment among healthcare professionals. Through initiatives like the ATLAS-Asthma program and targeted webinars, we’re highlighting the risks of steroid overuse and the role of biologics in optimising treatment. In parallel, collaboration with patient advocacy groups helps empower patients to take a more active role in their care.
- In Japan, national asthma guidelines were updated to include “asthma remission” as the goal for asthma treatment management.
- In China, the CARE4ALL program educates healthcare professionals on the latest evidence-based therapy recommendations from the Global Initiative for Asthma (GINA).
- In 2025, Malaysia launched Project ERASED to identify SABA over-reliance and strengthen the management of high-risk asthma patients in primary care. Through this initiative, over 600 healthcare professionals were engaged in educational workshops, and more than 90% endorsed efforts to reduce SABA-only reliever use in alignment with GINA recommendations.2 The public awareness campaign achieved significant success, engaging 1.6 million people nationwide. Building on this momentum, Malaysia introduced Project REGAIN in 2026, reinforcing our commitment to helping patients regain better asthma control.
Our aim with Project REGAIN is to help save thousands of Malaysians living with asthma by guiding them to appropriate, guideline‑directed anti‑inflammatory treatment.
5. Pioneering Innovation Across All Asthma Severities
Asthma care spans a wide spectrum, from mild to moderate to severe cases – all of which require a different medicine with varying modalities and targets to control disease. We’re working to change the asthma treatment paradigm with new medicines in development. The introduction of more innovative therapies could expand treatment access to an even broader range of patients. We are committed to this innovation that would support patients across the entire spectrum of disease.
Developments into novel ways to better manage asthma could potentially broaden access to therapies for patients whose disease is not controlled. Our goal is simple: to eliminate asthma attacks to improve quality of life for all people living with asthma.
It’s our global imperative to ensure that every person with asthma has the opportunity to thrive. We’re not just treating the disease – we’re transforming access by reducing barriers, empowering healthcare systems and ensuring every patient’s breath counts.
